A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine

NCT01003093 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

NCT01424501 ·Status: TERMINATED ·Phase: PHASE2

Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

NCT04874948 ·Status: COMPLETED ·Phase: PHASE1

Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide

NCT04694586 ·Status: SUSPENDED ·Phase: PHASE2

A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

NCT05284812 ·Status: SUSPENDED ·Phase: PHASE2

Ultra Curto (Ultra Short) TB Prevention Therapy

NCT04703075 ·Status: COMPLETED ·Phase: PHASE4

Tuberculosis Immunity in Children

NCT00170638 ·Status: COMPLETED

Safety and Risk of Sensitisation of the rdESAT-6 + rCFP-10 Skin Test Following Repeated Intradermal Administration

NCT00793702 ·Status: COMPLETED ·Phase: PHASE1

A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers

NCT00929396 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB Patients

NCT05136833 ·Status: WITHDRAWN ·Phase: PHASE2

Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients

NCT05571735 ·Status: RECRUITING

The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

NCT06580639 ·Status: RECRUITING

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

NCT02581527 ·Status: COMPLETED ·Phase: PHASE3

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671 ·Status: COMPLETED ·Phase: PHASE1

A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis

NCT01033929 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

NCT00341328 ·Status: COMPLETED ·Phase: PHASE3

Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination

NCT05165719 ·Status: COMPLETED

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

NCT06081361 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Functional Exhaustion of T Cells in COVID19 Patients

NCT04470323 ·Status: UNKNOWN

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

NCT05746611 ·Status: COMPLETED ·Phase: PHASE4

A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

NCT02606214 ·Status: TERMINATED ·Phase: PHASE1

TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB

NCT00664313 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.

NCT01223534 ·Status: COMPLETED ·Phase: PHASE4

Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

NCT00001318 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis

NCT01638520 ·Status: UNKNOWN ·Phase: PHASE2